Purpose: This wisdom of experience commentary, from peer academic reviewers serving on accreditation teams, will discuss benefits and challenges of international and national virtual accreditation visits (VAVs) using a "What? So What? Now What?" reflective model.
Description: Onsite accreditation reviews for health professional education programs require investments in time, effort, and money to maintain program alignment with accreditation standards and continuously generate quality practitioners. When COVID-19 entered the accreditation world, reviewers had to pivot modalities to a VAV format.
Analysis/interpretation: Adaptation and expectations of VAVs present several challenges. Barriers and advantages will be discussed as well as implications for the future. While medical and pharmacy education standardization has long been established, the authors propose national and international accrediting bodies will utilize the ingenuity of emergency COVID-19-driven onsite accreditation alternatives to develop protocols for novel accreditation methodology.
Conclusions: Whether the continued mutation of COVID-19 prevents the return to previous accreditation visits or not, the experiences gained from the emergency-driven VAV, can inform and enrich accrediting bodies knowledge, theories, and practices of future VAVs.
Implications: Higher-education institutions, accreditation bodies, and government entities will use experiences during COVID-19 to transform and improve academic requirements and future practices. Even if there is a full return to onsite reviews, such guidelines or improved versions of them can be applied to situations where immobility or restricted mobility is an issue, such as in illness, pregnancy, travel, war, etc. It is crucial for educators and accrediting bodies to evolve as we navigate these unprecedented times.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898663 | PMC |
http://dx.doi.org/10.1016/j.cptl.2022.03.013 | DOI Listing |
Healthcare (Basel)
December 2024
Department of Oral Biochemistry, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.
Background/objectives: Periodontal disease is an infection of the surrounding and supporting tissues of the teeth. Several associations have been identified for systemic conditions. This study aimed to assess the awareness of pregnant women regarding the link between premature and low-weight births with periodontal diseases.
View Article and Find Full Text PDFSci Rep
December 2024
INSERM, IRD, ISSPAM, SESSTIM, Cancer, Biomedicine & Society Group, Ligue 2019 Accredited Team, Aix Marseille Univ, 13009, Marseille, France.
Our study aimed to report on variables associated with communicative health literacy (COM-HL) in European adults. The HLS survey was conducted in 2019-2021 including nine countries which measured COM-HL by using a validated questionnaire (HLS-COM-P-Q6 with a score ranging from 0 to 100). Linear regression models were used to study variables associated with COM-HL globally (multilevel model with random intercepts and slopes and at country level) and in each country.
View Article and Find Full Text PDFAnimals (Basel)
November 2024
School of Law and Social Sciences, Oxford Brookes University, Oxford OX3 0BP, UK.
Eur J Obstet Gynecol Reprod Biol
January 2025
Chief Perinatal Centre of the institute for the care of mother and child, 3rd Medical School of Charles, University of Prague, Czech Republic, Chief WHO Collaborating centre in perinatal medicine, Prague, Czech Republic and Chair EBCOG Standing Committee on Training Recognition, Leuven, Belgium.
Ther Adv Neurol Disord
November 2024
The University of Texas Southwestern Medical Center, Department of Neurology, Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, Dallas, TX, USA.
An expansion in the availability of generic specialty disease modifying therapies (DMTs) for treatment of multiple sclerosis (MS) has increased recently. Generic specialty medications aim to provide greater access to molecules that alter the disease trajectory at lower costs. The US Food and Drug Administration requires generic products to contain between 90% and 110% of the stated active ingredient and an 80%-125% bioequivalence range.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!